Immunovant, Inc. Quarterly Current Income Tax Expense (Benefit) in USD for Q3 2019

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.
Summary
Immunovant, Inc. annual/quarterly Current Income Tax Expense (Benefit) history and growth rate for Q3 2019.
  • Immunovant, Inc. Current Income Tax Expense (Benefit) for the quarter ending September 30, 2019 was $138K.
  • Immunovant, Inc. annual Current Income Tax Expense (Benefit) for 2023 was $567K, a 6200% increase from 2022.
  • Immunovant, Inc. annual Current Income Tax Expense (Benefit) for 2022 was $9K.
  • Immunovant, Inc. annual Current Income Tax Expense (Benefit) for 2021 was -$84K, a 76.5% increase from 2020.
Current Income Tax Expense (Benefit), Quarterly (USD)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2019 $138K Jul 1, 2019 Sep 30, 2019 10-Q 2019-11-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.